Bristol-Myers Squibb

Trials

Studies that name Bristol-Myers Squibb as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:53 UTC. Showing 200 of 1762. Open this list on ClinicalTrials.gov

• Ph1
  NCT07887763 · A Phase 1 Study to Evaluate Safety, Tolerability, and Drug Levels of BMS-986485 in Healthy Adult Participants

  Bristol-Myers Squibb · not yet recruiting · Healthy Volunteers · study director
• Ph1
  NCT07873931 · A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

  Bristol-Myers Squibb · not yet recruiting · Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis · study director
• Ph2
  NCT07871214 · A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

  Bristol-Myers Squibb · not yet recruiting · Early-Stage Non-Small Cell Lung Cancer · study director
• N/A
  NCT07852884 · First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain

  Bristol-Myers Squibb · active not recruiting · Renal Cell Carcinoma (RCC) · study director
• Ph1
  NCT07852962 · Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants.

  Bristol-Myers Squibb · not yet recruiting · Healthy Volunteers · study director
• Ph1
  NCT07848295 · A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · not yet recruiting · Clear Cell Renal Cell Carcinoma (ccRCC) · study director
• N/A
  NCT07846059 · Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy

  Bristol-Myers Squibb · not yet recruiting · Obstructive Hypertrophic Cardiomyopathy (oHCM) · study director
• Ph1
  NCT07837115 · A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult Participants

  Celgene · recruiting · Healthy Volunteers · study director
• Ph1
  NCT07800897 · A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants

  Bristol-Myers Squibb · recruiting · Healthy Female Adults · study director
• Ph3
  NCT07791199 · Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

  Bristol-Myers Squibb · not yet recruiting · Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis · study director
• N/A
  NCT07783373 · Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia

  Bristol-Myers Squibb · active not recruiting · Schizophrenia · study director
• Ph1
  NCT07780383 · A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

  Bristol-Myers Squibb · recruiting · Alzheimer's Disease, Healthy Participants · study director
• Ph1
  NCT07777133 · A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants

  Bristol-Myers Squibb · recruiting · Healthy Female Participants · study director
• N/A
  NCT07777120 · Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma

  Bristol-Myers Squibb · active not recruiting · Marginal Zone Lymphoma
• Ph2
  NCT07772531 · A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

  Bristol-Myers Squibb · not yet recruiting · Major Depressive Disorder · study director
• Ph1
  NCT07763418 · A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

  Bristol-Myers Squibb · recruiting · Kidney Failure, Chronic · study director
• N/A
  NCT07755826 · Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan

  Bristol-Myers Squibb · recruiting · NTRK Fusion-positive Solid Tumors
• N/A
  NCT07752121 · First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

  Bristol-Myers Squibb · recruiting · Myelodysplastic Neoplasms · study director
• N/A
  NCT07732907 · Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia

  Bristol-Myers Squibb · recruiting · Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy · study director
• Ph1
  NCT07723118 · A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

  Mirati Therapeutics Inc. · completed · Healthy Participants · study director
• N/A
  NCT07722507 · Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis

  Bristol-Myers Squibb · not yet recruiting · Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis · study director
• N/A
  NCT07718139 · Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada

  Bristol-Myers Squibb · active not recruiting · Non-Small Cell Lung Cancer · study director
• Ph1
  NCT07700329 · A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants

  Celgene · not yet recruiting · Healthy Volunteers · study director
• N/A
  NCT07689006 · Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens

  Bristol-Myers Squibb · completed · Relapsed/Refractory Multiple Myeloma
• Ph3
  NCT07686263 · Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · recruiting · Schizophrenia · study director
• Ph3
  NCT07680790 · Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  Bristol-Myers Squibb · recruiting · Non-Small Cell Lung Cancer · study director
• Ph4
  NCT07681076 · Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · recruiting · Healthy Volunteers · study director
• Ph2
  NCT07680764 · A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  Bristol-Myers Squibb · recruiting · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC) · study director
• N/A
  NCT07681440 · A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia

  Bristol-Myers Squibb · terminated · Myelodysplastic Syndromes, Beta-thalassemia
• N/A
  NCT07679061 · First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

  Bristol-Myers Squibb · recruiting · Unresectable Hepatocellular Carcinoma · study director
• N/A
  NCT07663786 · Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice

  Bristol-Myers Squibb · active not recruiting · Esophageal Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Gastric Adenocarcinoma · study director
• Ph1
  NCT07655518 · A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

  Bristol-Myers Squibb · recruiting · Healthy Volunteers · study director
• N/A
  NCT07636863 · Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

  Bristol-Myers Squibb · completed · Cancer
• Ph1
  NCT07629999 · Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

  Bristol-Myers Squibb · recruiting · Healthy Volunteers · study director
• Ph2
  NCT07603557 · Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · not yet recruiting · Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia · study director
• N/A
  NCT07599007 · Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

  Bristol-Myers Squibb · not yet recruiting · Non-Small Cell Lung Cancer · study director
• N/A
  NCT07571148 · Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

  Bristol-Myers Squibb · completed · Schizophrenia
• N/A
  NCT07557498 · Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

  Bristol-Myers Squibb · recruiting · Obstructive Hypertrophic Cardiomyopathy (oHCM) · study director
• Ph1
  NCT07544628 · A Phase 1 Study of Navlimetostat Tablet Formulations

  Bristol-Myers Squibb · recruiting · Healthy Participants · study director
• N/A
  NCT07526961 · Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

  Bristol-Myers Squibb · completed · Non-Small Cell Lung Cancer · study director
• Ph2
  NCT07492680 · A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  Bristol-Myers Squibb · recruiting · Solid Tumors · study director
• N/A
  NCT07465029 · A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

  Bristol-Myers Squibb · active not recruiting · Lower-risk Myelodysplastic Syndromes (TD LR-MDS) · study director
• Ph4
  NCT07459543 · A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India

  Bristol-Myers Squibb · not yet recruiting · Unresectable Melanoma, Metastatic Melanoma · study director
• N/A
  NCT07458542 · Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia

  Bristol-Myers Squibb · completed · Acute Myeloid Leukemia (AML)
• Ph3
  NCT07441408 · Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  Bristol-Myers Squibb · not yet recruiting · Pulmonary Fibrosis · study director
• N/A
  NCT07434960 · Expanded Access for Iberdomide

  Bristol-Myers Squibb · available · study director
• Ph3
  NCT07424404 · A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · recruiting · Schizophrenia, Autism-Related Irritability · study director
• Ph1
  NCT07422298 · A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

  Bristol-Myers Squibb · completed · Healthy Volunteers · study director
• Ph1/Ph2
  NCT07412704 · A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

  Bristol-Myers Squibb · recruiting · Arthritis, Rheumatoid · study director
• Ph2
  NCT07415031 · A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

  Mirati Therapeutics Inc. · recruiting · Solid Tumors · study director
• N/A
  NCT07383025 · Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

  Bristol-Myers Squibb · recruiting · Obstructive Hypertrophic Cardiomyopathy (oHCM)
• N/A
  NCT07379827 · Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

  Bristol-Myers Squibb · recruiting · Schizophrenia
• Ph3
  NCT07361497 · A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  Bristol-Myers Squibb · recruiting · Non-small Cell Lung Cancer (NSCLC) · study director
• Ph3
  NCT07361510 · A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  Bristol-Myers Squibb · recruiting · Non-Small Cell Lung Cancer (NSCLC) · study director
• N/A
  NCT07361289 · A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

  Bristol-Myers Squibb · recruiting · Hypertrophic Cardiomyopathy
• N/A
  NCT07355478 · Asia Myelodysplastic Syndrome (MDS) Registry

  Bristol-Myers Squibb · recruiting · Myelodysplastic Syndromes (MDS) · study director
• Ph3
  NCT07335562 · A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · not yet recruiting · Systemic Sclerosis · study director
• Ph1/Ph2
  NCT07325136 · A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

  Bristol-Myers Squibb · recruiting · Relapsed/Refractory Small Cell Lung Cancer · study director
• Ph1/Ph2
  NCT07293351 · A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  Bristol-Myers Squibb · recruiting · Advanced Renal Cell Carcinoma (RCC) · study director
• Ph1/Ph2
  NCT07291076 · A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  Bristol-Myers Squibb · recruiting · Hepatocellular Carcinoma (HCC) · study director
• Ph3
  NCT07288567 · A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

  Bristol-Myers Squibb · recruiting · Schizophrenia · study director
• Ph3
  NCT07285798 · A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

  Bristol-Myers Squibb · recruiting · Irritability Associated With Autism Spectrum Disorder · study director
• Ph3
  NCT07284745 · A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

  Bristol-Myers Squibb · recruiting · Irritability Associated With Autism Spectrum Disorder · study director
• Ph1
  NCT07283263 · A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

  Bristol-Myers Squibb · recruiting · Healthy Volunteers · study director
• N/A
  NCT07271069 · Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

  Bristol-Myers Squibb · recruiting · Ulcerative Colitis (UC)
• Ph4
  NCT07257120 · KarXT Concentrations in the Breast Milk and Plasma of Lactating Females

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · completed · Healthy Volunteers · study director
• N/A
  NCT07256015 · Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

  Bristol-Myers Squibb · active not recruiting · Psoriasis · study director
• Ph1
  NCT07248839 · A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

  Bristol-Myers Squibb · completed · Healthy Volunteers, Hepatic Impairment · study director
• Ph1
  NCT07242781 · A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

  Celgene · terminated · Healthy Volunteers · study director
• Ph1
  NCT07226817 · A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

  Bristol-Myers Squibb · recruiting · Healthy Volunteers · study director
• Ph1
  NCT07225647 · A Study to Assess the Effect of Food on the Drug Levels of Admilparant

  Bristol-Myers Squibb · completed · Healthy Participants · study director
• Ph1
  NCT07223671 · Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

  Bristol-Myers Squibb · completed · Healthy Volunteers · study director
• Ph1/Ph2
  NCT07223047 · A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

  Bristol-Myers Squibb · recruiting · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) · study director
• Ph4
  NCT07221877 · A Study to Evaluate the Effect of KarXT on Urological Safety

  Bristol-Myers Squibb · recruiting · Schizophrenia · study director
• Ph2/Ph3
  NCT07221357 · A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  Bristol-Myers Squibb · recruiting · Untreated, Unresectable, or Metastatic Colorectal Cancer · study director
• Ph2/Ph3
  NCT07221149 · A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  Bristol-Myers Squibb · recruiting · Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma · study director
• N/A
  NCT07215975 · A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

  Bristol-Myers Squibb · recruiting · β-thalassemia
• N/A
  NCT07215962 · Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

  Bristol-Myers Squibb · completed · Non-small Cell Lung Cancer (NSCLC)
• Ph1
  NCT07204418 · A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · recruiting · Healthy Volunteers · study director
• Ph1
  NCT07195682 · A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

  Bristol-Myers Squibb · recruiting · Renal Cell Carcinoma · study director
• N/A
  NCT07175285 · A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  Bristol-Myers Squibb · recruiting · Systemic Lupus Erythematosus (SLE)
• Ph1
  NCT07171983 · A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

  Bristol-Myers Squibb · recruiting · Rheumatoid Arthritis · study director
• N/A
  NCT07168655 · Mavacamten in Obstructive Hypertrophic Cardiomyopathy

  Bristol-Myers Squibb · completed · Obstructive Hypertrophic Cardiomyopathy (oHCM)
• Ph1/Ph2
  NCT07160725 · A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

  Bristol-Myers Squibb · recruiting · Solid Tumours · study director
• Ph3
  NCT07140913 · A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

  Bristol-Myers Squibb · recruiting · Mania, Bipolar Disorder · study director
• N/A
  NCT07141563 · A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

  Bristol-Myers Squibb · completed · Non-small Cell Lung Cancer (NSCLC)
• Ph1
  NCT07118215 · A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · completed · Healthy Volunteers · study director
• Ph3
  NCT07116967 · Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  Bristol-Myers Squibb · recruiting · Plaque Psoriasis · study director
• Ph1
  NCT07115745 · A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · recruiting · Refractory Autoimmune Diseases · study director
• N/A
  NCT07107373 · A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

  Bristol-Myers Squibb · active not recruiting · Obstructive Hypertrophic Cardiomyopathy (oHCM) · study director
• Ph2/Ph3
  NCT07106762 · Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  Bristol-Myers Squibb · recruiting · Urothelial Cancer · study director
• Ph2/Ph3
  NCT07100080 · Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  Bristol-Myers Squibb · recruiting · Non-Small Cell Lung Cancer · study director
• N/A
  NCT07101094 · Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

  Bristol-Myers Squibb · recruiting · Schizophrenia
• N/A
  NCT07091695 · Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

  Bristol-Myers Squibb · completed · Melanoma
• N/A
  NCT07079644 · Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

  Bristol-Myers Squibb · completed · Advanced Melanoma
• Ph1
  NCT07077434 · A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

  Bristol-Myers Squibb · recruiting · Advanced Solid Tumors · study director
• Ph2/Ph3
  NCT07076121 · A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  Bristol-Myers Squibb · active not recruiting · Pancreatic Ductal Adenocarcinoma · study director
• N/A
  NCT07075406 · A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept

  Bristol-Myers Squibb · completed · Myelodysplastic Syndromes
• N/A
  NCT07073690 · Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

  Bristol-Myers Squibb · completed · Myelodysplastic Syndromes
• Ph2/Ph3
  NCT07063745 · A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  Bristol-Myers Squibb · recruiting · Metastatic Non-small Cell Lung Cancer With MTAP Deletion · study director
• Ph1
  NCT07063342 · A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses

  Bristol-Myers Squibb · recruiting · Healthy Volunteers · study director
• Ph1
  NCT07061288 · A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

  Bristol-Myers Squibb · recruiting · Schizophrenia · study director
• N/A
  NCT07024862 · Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

  Bristol-Myers Squibb · completed · Metastatic Non-small Cell Lung Cancer
• N/A
  NCT07017699 · A Study to Assess Deucravacitinib Safety in Pregnancy

  Bristol-Myers Squibb · recruiting · Psoriasis (PsO)
• Ph2
  NCT07015983 · A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · active not recruiting · Lupus Erythematosus, Systemic, Lupus Nephritis · study director
• Ph2
  NCT07015242 · A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · recruiting · Lymphoma · study director
• Ph3
  NCT07011745 · A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  Bristol-Myers Squibb · recruiting · Alzheimer's Disease · study director
• Ph3
  NCT07011732 · A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  Bristol-Myers Squibb · recruiting · Alzheimer Disease · study director
• N/A
  NCT07008820 · Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan

  Bristol-Myers Squibb · completed · Myelodysplastic Syndrome (MDS) · study director
• Ph4
  NCT07004972 · A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

  Bristol-Myers Squibb · active not recruiting · Symptomatic Obstructive Hypertrophic Cardiomyopathy · study director
• Ph1
  NCT06997029 · A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

  Bristol-Myers Squibb · recruiting · Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer · study director
• N/A
  NCT06994117 · Expanded Access for Mezigdomide

  Bristol-Myers Squibb · available · study director
• Ph1/Ph2
  NCT06988488 · A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

  Celgene · recruiting · Multiple Myeloma · study director
• Ph3
  NCT06979453 · A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  Bristol-Myers Squibb · recruiting · Plaque Psoriasis · study director
• Ph3
  NCT06976203 · A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  Bristol-Myers Squibb · recruiting · Alzheimer's Disease · study director
• Ph3
  NCT06976216 · A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  Bristol-Myers Squibb · recruiting · Alzheimer's Disease · study director
• N/A
  NCT06971185 · A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

  Bristol-Myers Squibb · completed · Myelodysplastic Syndromes (MDS)
• Ph1
  NCT06955741 · A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

  Bristol-Myers Squibb · completed · Healthy Volunteer · study director
• N/A
  NCT06952465 · A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

  Bristol-Myers Squibb · active not recruiting · Psoriasis
• Ph3
  NCT06951698 · A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

  Bristol-Myers Squibb · recruiting · Bipolar-I Disorder With Mania or Mania With Mixed Features · study director
• Ph3
  NCT06951711 · A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

  Bristol-Myers Squibb · recruiting · Bipolar Disorder Type I With Mania or Mania With Mixed Features · study director
• Ph2
  NCT06946797 · A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

  Bristol-Myers Squibb · active not recruiting · Non-Small Cell Lung Cancer · study director
• Ph3
  NCT06947941 · A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

  Bristol-Myers Squibb · recruiting · Alzheimer Disease, Psychosis · study director
• Ph3
  NCT06937229 · A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  Bristol-Myers Squibb · recruiting · Alzheimer Disease, Agitation · study director
• Ph3
  NCT06929273 · A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  Bristol-Myers Squibb · recruiting · Bipolar Disorder Type I With Mania · study director
• Ph2/Ph3
  NCT06926868 · A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  Bristol-Myers Squibb · recruiting · Breast Neoplasms · study director
• Ph3
  NCT06911502 · A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  Celgene · recruiting · Follicular Lymphoma
• Ph3
  NCT06882785 · A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

  Bristol-Myers Squibb · recruiting · Schizophrenia · study director
• Ph4
  NCT06875960 · A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

  Bristol-Myers Squibb · recruiting · Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) · study director
• Ph1
  NCT06877702 · A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

  Bristol-Myers Squibb · completed · Healthy Volunteers · study director
• Ph3
  NCT06875310 · A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  Mirati Therapeutics Inc. · recruiting · Carcinoma, Non-Small-Cell Lung · study director
• Ph3
  NCT06869551 · A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

  Bristol-Myers Squibb · recruiting · Juvenile Psoriatic Arthritis · study director
• Ph2
  NCT06855771 · A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

  Bristol-Myers Squibb · recruiting · Carcinoma, Non-Small-Cell Lung · study director
• Ph1
  NCT06853171 · Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

  Bristol-Myers Squibb · completed · Psychiatric Disorders
• N/A
  NCT06851065 · A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States

  Bristol-Myers Squibb · completed · Myelodysplastic Syndromes
• Ph1
  NCT06851871 · A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

  Bristol-Myers Squibb · completed · Healthy Participants · study director
• Ph1
  NCT06846866 · A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

  Bristol-Myers Squibb · completed · Healthy Volunteers · study director
• Ph2
  NCT06808984 · Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

  Celgene · recruiting · Agitation, Alzheimer Disease · study director
• Ph1
  NCT06801418 · Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets

  Mirati Therapeutics Inc. · completed · Healthy Volunteers · study director
• Ph1
  NCT06799286 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

  Bristol-Myers Squibb · completed · Small Cell Lung Carcinoma · study director
• N/A
  NCT06794268 · A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · recruiting · Follicular Lymphoma · study director
• N/A
  NCT06788639 · A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · recruiting · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) · study director
• N/A
  NCT06788652 · A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · recruiting · Mantle Cell Lymphoma (MCL) · study director
• Ph2
  NCT06782490 · A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

  Celgene · recruiting · Multiple Sclerosis Spasticity · study director
• Ph1
  NCT06764771 · A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

  Bristol-Myers Squibb · recruiting · Advanced Malignant Tumors · study director
• Ph3
  NCT06764485 · A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

  Celgene · active not recruiting · Metastatic Castration-resistant Prostate Cancer · study director
• Ph1
  NCT06746402 · A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

  Bristol-Myers Squibb · completed · Healthy Volunteers · study director
• N/A
  NCT06735781 · Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

  Bristol-Myers Squibb · completed · Non-small Cell Lung Cancer (NSCLC)
• Ph1/Ph2
  NCT06730750 · A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

  Bristol-Myers Squibb · active not recruiting · Advanced Solid Tumors · study director
• Ph1
  NCT06729970 · A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · completed · Healthy Volunteers · study director
• Ph1
  NCT06723535 · A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

  Bristol-Myers Squibb · completed · Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment · study director
• Ph1
  NCT06715683 · A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

  Bristol-Myers Squibb · completed · Healthy Volunteers · study director
• N/A
  NCT06710470 · A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

  Bristol-Myers Squibb · active not recruiting · Psoriasis · study director
• N/A
  NCT06701513 · A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

  Bristol-Myers Squibb · recruiting · Psoriasis · study director
• N/A
  NCT06698887 · A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

  Bristol-Myers Squibb · recruiting · Multiple Myeloma · study director
• Ph1/Ph2
  NCT06697197 · A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

  Bristol-Myers Squibb · recruiting · Advanced Solid Tumors · study director
• Ph1
  NCT06672523 · A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

  Bristol-Myers Squibb · recruiting · Advanced Solid Tumors With Homozygous MTAP Deletion · study director
• Ph3
  NCT06646276 · A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  Bristol-Myers Squibb · recruiting · Extensive-Stage Small Cell Lung Cancer · study director
• Ph1/Ph2
  NCT06618287 · A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  Bristol-Myers Squibb · recruiting · Lung Cancer, Breast Cancer · study director
• Ph3
  NCT06615479 · A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · recruiting · Relapsed or Refractory Multiple Myeloma (RRMM) · study director
• Ph1
  NCT06605950 · A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · completed · Healthy Volunteers · study director
• Ph3
  NCT06585787 · A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · recruiting · Alzheimer Disease · study director
• N/A
  NCT06596642 · A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan

  Bristol-Myers Squibb · completed · β-Thalassemia Major · study director
• N/A
  NCT06581055 · A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

  Bristol-Myers Squibb · withdrawn · Myelodysplastic Syndromes (MDS) · study director
• Ph1
  NCT06577259 · Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

  Bristol-Myers Squibb · completed · Healthy Participants · study director
• Ph3
  NCT06572449 · Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

  Karuna Therapeutics, Inc., a Bristol Myers Squibb company · completed · Schizophrenia · study director
• Ph1
  NCT06568458 · A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

  Bristol-Myers Squibb · completed · Healthy Participants · study director
• N/A
  NCT06565975 · Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France

  Bristol-Myers Squibb · completed · Acute Myeloid Leukemia (AML) · study director
• Ph1
  NCT06566768 · Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants

  Bristol-Myers Squibb · completed · Healthy Participants · study director
• Ph3
  NCT06561386 · A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  Bristol-Myers Squibb · recruiting · Non-small Cell Lung Cancer · study director
• N/A
  NCT06551129 · Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

  Bristol-Myers Squibb · recruiting · Obstructive Hypertrophic Cardiomyopathy · study director
• N/A
  NCT06549608 · A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

  Bristol-Myers Squibb · completed · Hypertrophic Cardiomyopathy · study director
• Ph1
  NCT06544655 · A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

  Bristol-Myers Squibb · active not recruiting · Advanced Solid Tumors · study director
• Ph1
  NCT06535399 · Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

  Celgene · completed · Hepatic Impairment, Healthy Volunteers · study director
• N/A
  NCT06512337 · A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

  Bristol-Myers Squibb · active not recruiting · Plaque Psoriasis · study director
• N/A
  NCT06504615 · Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

  Bristol-Myers Squibb · active not recruiting · Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma (EAC) · study director
• N/A
  NCT06499298 · Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

  Bristol-Myers Squibb · completed · Esophageal Cancer, Gastroesophageal Junction Cancer · study director
• Ph1
  NCT06493409 · A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

  Bristol-Myers Squibb · completed · Healthy Volunteers · study director
• N/A
  NCT06487156 · A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  Bristol-Myers Squibb · active not recruiting · Non-small Cell Lung Cancer (NSCLC) · study director
• Ph1/Ph2
  NCT06481306 · A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

  Bristol-Myers Squibb · recruiting · Anemia, Sickle Cell, Healthy Volunteers · study director
• Ph4
  NCT06476834 · A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

  Bristol-Myers Squibb · completed · Healthy Volunteers · study director
• Ph1
  NCT06476808 · A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

  Bristol-Myers Squibb · recruiting · High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC) · study director
• Ph1
  NCT06476821 · A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants

  Bristol-Myers Squibb · completed · Healthy Volunteers · study director
• N/A
  NCT06452329 · A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

  Bristol-Myers Squibb · completed · Gastric Cancer, Gastroesophageal Junction Cancer · study director
• N/A
  NCT06448793 · Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

  Bristol-Myers Squibb · completed · Non-small Cell Lung Cancer (NSCLC) · study director
• Ph1
  NCT06433505 · A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

  Celgene · completed · Healthy Volunteers · study director
• Ph2
  NCT06425302 · A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

  Celgene · active not recruiting · Lymphoma, Follicular · study director
• Ph1
  NCT06425198 · Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

  Bristol-Myers Squibb · completed · Hepatic Impairment, Healthy Participants · study director
• N/A
  NCT06421311 · Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

  Bristol-Myers Squibb · terminated · Urothelial Carcinoma · study director
• N/A
  NCT06422247 · Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

  Bristol-Myers Squibb · completed · Peripheral T-cell Lymphoma · study director
• Ph1
  NCT06419634 · Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

  Bristol-Myers Squibb · terminated · Acute Myeloid Leukemia, Myelodysplastic Syndrome · study director
• Ph1
  NCT06417229 · Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

  Celgene · completed · Healthy Participants · study director
• Ph1
  NCT06411730 · A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

  Celgene · completed · Healthy Participants · study director
• Ph3
  NCT06408259 · Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

  Bristol-Myers Squibb · recruiting · Multiple Sclerosis, Relapsing-Remitting · study director
• Ph4
  NCT06396039 · A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

  Bristol-Myers Squibb · active not recruiting · Relapsing Multiple Sclerosis · study director
• N/A
  NCT06382987 · A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

  Bristol-Myers Squibb · recruiting · Plaque Psoriasis · study director
• N/A
  NCT06372457 · COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

  Bristol-Myers Squibb · active not recruiting · Hypertrophic Cardiomyopathy (HCM) · study director
• Ph1
  NCT06363630 · A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

  Celgene · completed · Healthy Volunteers · study director
• N/A
  NCT06361563 · Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

  Bristol-Myers Squibb · completed · Upper Gastrointestinal Cancer · study director
• N/A
  NCT06361576 · Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

  Bristol-Myers Squibb · completed · Upper Gastrointestinal Cancer

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.